Atopic Dermatitis

WASHINGTON — Ruxolitinib was efficacious and well tolerated in pediatric patients with mild to moderate atopic dermatitis, according to a poster presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

WASHINGTON — Patients with moderate to severe atopic dermatitis treated with lebrikizumab maintained improvements in patient-reported outcomes, according to a poster presented here.

WASHINGTON — Patients with atopic dermatitis may have better outcomes when using liquid synthetic detergents, according to a poster presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

WASHINGTON — Among children with atopic dermatitis, low non-lesional skin filaggrin expression during early ages predicted future asthma, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

WASHINGTON — Treatment with 1% tapinarof cream led to symptom improvements for most patients with atopic dermatitis, according to a poster presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

The FDA has approved Xolair for the reduction of allergic reactions in children and adults with immunoglobulin E-mediated food allergy, according to a press release from Roche.

Data showed that not all patients with chronic inflammatory skin diseases undergo pretreatment testing before initiating systemic immunomodulatory therapies, despite current guidelines, according to a study.

MIAMI BEACH, Fla. — Zabalafin, a nonsteroidal topical, demonstrated efficacy in reducing inflammation and bacteria on the skin of children and adults with atopic dermatitis, according to interim data presented in a poster at Masters of Pediatric Dermatology.

In this video, Raj Chovatiya, MD, PhD, discussed research into the OX40 inhibitor amlitelimab, as well as two topical medications, from the Maui Derm 2024 meeting, examining data into their use in treating atopic dermatitis.